Curran, Kevin J

Publications

Sort by

Co-Author Network

selected publications

Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone marrow transplantation. 2020 Academic Article GET IT
Times cited: 11
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 176
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 59
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Molecular therapy. Methods & clinical development. 2018 Academic Article GET IT
Times cited: 23
Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine. Journal of pediatric hematology/oncology. 2018 Academic Article GET IT
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Information Resource GET IT
Times cited: 63
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1935
Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors. Pediatric hematology and oncology. 2016 Academic Article GET IT
Times cited: 3
Toxicity and management in CAR T-cell therapy. Molecular therapy oncolytics. 2016 Information Resource GET IT
Times cited: 680
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Molecular therapy : the journal of the American Society of Gene Therapy. 2015 Academic Article GET IT
Times cited: 199
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 2060
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. International journal of hematology. 2013 Information Resource GET IT
Times cited: 91
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science translational medicine. 2013 Academic Article GET IT
Times cited: 1704
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. The journal of gene medicine. 2012 Information Resource GET IT
Times cited: 200
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology. American Society of Hematology. Education Program. 2012 Information Resource GET IT
Times cited: 72
Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatric blood & cancer. 2011 Academic Article GET IT
Times cited: 30
Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors. Bioorganic & medicinal chemistry letters. 2010 Academic Article GET IT
Times cited: 37
2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability. Bioorganic & medicinal chemistry letters. 2010 Academic Article GET IT
Times cited: 25
Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition. Journal of medicinal chemistry. 2010 Academic Article GET IT
Times cited: 24
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer research. 2010 Academic Article GET IT
Times cited: 174
Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent. Bioorganic & medicinal chemistry letters. 2010 Academic Article GET IT
Times cited: 58
Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent. Journal of medicinal chemistry. 2009 Academic Article GET IT
Times cited: 54
Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. Journal of medicinal chemistry. 2009 Academic Article GET IT
Times cited: 88
Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase. Journal of medicinal chemistry. 2009 Academic Article GET IT
Times cited: 49
Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability. Bioorganic & medicinal chemistry letters. 2009 Academic Article GET IT
Times cited: 42
ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. Journal of medicinal chemistry. 2009 Academic Article GET IT
Times cited: 96
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer research. 2009 Academic Article GET IT
Times cited: 292
Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. Journal of medicinal chemistry. 2007 Academic Article GET IT
Times cited: 55
Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. Journal of medicinal chemistry. 2006 Academic Article GET IT
Times cited: 61
Measurement of apoptosis of intact human islets by confocal optical sectioning and stereologic analysis of YO-PRO-1-stained islets. Transplantation. 2005 Academic Article GET IT
Times cited: 20
Thiourea inhibitors of herpesviruses. Part 3: Inhibitors of varicella zoster virus. Bioorganic & medicinal chemistry letters. 2004 Academic Article GET IT
Times cited: 27
Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N'-arylthiourea inhibitors of CMV. Bioorganic & medicinal chemistry letters. 2004 Academic Article GET IT
Times cited: 48
Pyrimido[1,2-b]-1,2,4,5-tetrazin-6-ones as HCMV protease inhibitors: a new class of heterocycles with flavin-like redox properties. Bioorganic & medicinal chemistry letters. 2003 Academic Article GET IT
Times cited: 16
Thiourea inhibitors of herpes viruses. Part 1: bis-(aryl)thiourea inhibitors of CMV. Bioorganic & medicinal chemistry letters. 2003 Academic Article GET IT
Times cited: 36
Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. Journal of virology. 2003 Academic Article GET IT
Times cited: 42

more ...

less ...

Background

education and training

M.D., Georgetown University School of Medicine 2004
B.S., Villanova University 2000

Contact

full name

Kevin J Curran

VIVO Weill Cornell Medical College

Kevin J Curran Associate Professor of Pediatrics

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name